Xarelto, an anticoagulant medication, generated approximately $2.1 billion in net sales for Johnson & Johnson in the first three quarters of 2023 [1]. This figure represents global sales across its pharmaceutical segment [1].
What is Xarelto used for?
Xarelto (rivaroxaban) is prescribed to prevent blood clots in individuals with conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [2]. It is also used following knee or hip replacement surgery to reduce the risk of these clots [2].
How does Xarelto work?
Xarelto is a direct oral anticoagulant (DOAC) that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [3]. By blocking Factor Xa, Xarelto effectively reduces thrombin generation and prevents the formation of blood clots [3].
When does Xarelto's patent expire?
The patent exclusivity for Xarelto has been a subject of legal challenges and varying timelines depending on specific patents and regions. Information on Xarelto's patent status and potential expiry dates can be found through resources like DrugPatentWatch.com [4].
Who are Xarelto's main competitors?
Xarelto competes with other DOACs, including Eliquis (apixaban) from Bristol Myers Squibb and Pfizer, and Pradaxa (dabigatran) from Boehringer Ingelheim [5]. These drugs target similar indications for stroke prevention and treatment of blood clots [5].
What are the potential risks and side effects of Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [6]. This can range from minor bruising to severe, life-threatening hemorrhage [6]. Other potential side effects include dizziness, fatigue, and gastrointestinal issues [6].
Can generic versions of Xarelto be made?
The availability of generic versions of Xarelto depends on the expiration of its patents and any remaining market exclusivity granted by regulatory bodies [4]. Once patents expire and exclusivity periods end, generic manufacturers may be able to produce and market their own versions of rivaroxaban [4].
---
1. Johnson & Johnson. (2023). Johnson & Johnson Reports 2023 Third-Quarter Results.
2. Xarelto. (n.d.). Xarelto® (rivaroxaban) Prescribing Information.
3. Data on File. Janssen Pharmaceuticals, Inc.
4. DrugPatentWatch.com.
5. Setti, G., & Lip, G. Y. H. (2020). DOACs Versus VKAs in Atrial Fibrillation: Where Are We Now? Current Opinion in Cardiology, 35(1), 1–7.
6. Xarelto. (n.d.). Xarelto® (rivaroxaban) Patient Information.